Copyright
©The Author(s) 2017.
World J Gastroenterol. Jun 14, 2017; 23(22): 4102-4111
Published online Jun 14, 2017. doi: 10.3748/wjg.v23.i22.4102
Published online Jun 14, 2017. doi: 10.3748/wjg.v23.i22.4102
Table 2 Prevalence of liver injury events among all aminotransferase measurements in 251 inflammatory bowel disease patients over 1 year n (%)
| Liver injury event | All measurements | Abnormal |
| n | Number of events | |
| ALT increase Grade 1 (0-3 × ULN) | 917 | 112 (12.21) |
| ALT increase > 2 × ULN (hepatocellular injury) | 917 | 26 (2.84) |
| ALT increase Grade 2 (> 3 × ULN) | 917 | 6 (0.65) |
| AST increase Grade 1 (0-3 × ULN) | 917 | 55 (6.0) |
| AST increase Grade 2 (> 3 × ULN) | 917 | 8 (0.87) |
| GGT increase Grade 1 (0-2.5 × ULN) | 895 | 80 (8.94) |
| GGT increase Grade 2 (> 2.5 × ULN) | 895 | 24 (2.68) |
| ALP increase Grade 1 (0-2.5 × ULN) | 897 | 34 (3.79) |
| ALP increase Grade 2 (> 2.5 × ULN) | 897 | 0 (0) |
| Cholestasis (parallel ALP and GGT elevation) | 895 | 11 (1.23) |
| Total bilirubin > 2 × ULN | 370 | 1 (0.27) |
- Citation: Koller T, Galambosova M, Filakovska S, Kubincova M, Hlavaty T, Toth J, Krajcovicova A, Payer J. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. World J Gastroenterol 2017; 23(22): 4102-4111
- URL: https://www.wjgnet.com/1007-9327/full/v23/i22/4102.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i22.4102